NASDAQ:INMD

InMode Competitors

$87.31
-0.05 (-0.06 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$85.19
Now: $87.31
$88.17
50-Day Range
$64.23
MA: $73.06
$87.36
52-Week Range
$21.68
Now: $87.31
$88.59
Volume579,202 shs
Average Volume780,202 shs
Market Capitalization$2.79 billion
P/E Ratio62.81
Dividend YieldN/A
Beta1.95

Competitors

InMode (NASDAQ:INMD) Vs. LIVN, CNMD, OM, BLFS, NTUS, and AXGN

Should you be buying INMD stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to InMode, including LivaNova (LIVN), CONMED (CNMD), Outset Medical (OM), BioLife Solutions (BLFS), Natus Medical (NTUS), and AxoGen (AXGN).

InMode (NASDAQ:INMD) and LivaNova (NASDAQ:LIVN) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Profitability

This table compares InMode and LivaNova's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InMode32.57%28.56%24.14%
LivaNova-21.88%5.55%3.07%

Analyst Ratings

This is a breakdown of current ratings for InMode and LivaNova, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
InMode00403.00
LivaNova04202.33

InMode currently has a consensus price target of $71.50, suggesting a potential downside of 18.11%. LivaNova has a consensus price target of $69.3333, suggesting a potential downside of 14.76%. Given LivaNova's higher probable upside, analysts plainly believe LivaNova is more favorable than InMode.

Valuation and Earnings

This table compares InMode and LivaNova's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InMode$156.36 million17.85$61.15 million$1.6054.57
LivaNova$1.08 billion3.65$-155,180,000.00$3.0826.41

InMode has higher earnings, but lower revenue than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

35.7% of InMode shares are owned by institutional investors. Comparatively, 89.1% of LivaNova shares are owned by institutional investors. 0.5% of LivaNova shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

InMode has a beta of 1.95, suggesting that its share price is 95% more volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500.

Summary

InMode beats LivaNova on 9 of the 14 factors compared between the two stocks.

CONMED (NYSE:CNMD) and InMode (NASDAQ:INMD) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares CONMED and InMode's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CONMED0.04%9.48%3.75%
InMode32.57%28.56%24.14%

Analyst Recommendations

This is a breakdown of current ratings and target prices for CONMED and InMode, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CONMED02302.60
InMode00403.00

CONMED presently has a consensus target price of $103.25, suggesting a potential downside of 20.71%. InMode has a consensus target price of $71.50, suggesting a potential downside of 18.11%. Given InMode's stronger consensus rating and higher possible upside, analysts plainly believe InMode is more favorable than CONMED.

Valuation & Earnings

This table compares CONMED and InMode's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CONMED$955.10 million3.96$28.62 million$2.6449.32
InMode$156.36 million17.85$61.15 million$1.6054.57

InMode has lower revenue, but higher earnings than CONMED. CONMED is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

35.7% of InMode shares are owned by institutional investors. 5.4% of CONMED shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

CONMED has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500. Comparatively, InMode has a beta of 1.95, indicating that its share price is 95% more volatile than the S&P 500.

Summary

InMode beats CONMED on 11 of the 14 factors compared between the two stocks.

Outset Medical (NASDAQ:OM) and InMode (NASDAQ:INMD) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares Outset Medical and InMode's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Outset MedicalN/AN/AN/A
InMode32.57%28.56%24.14%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Outset Medical and InMode, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Outset Medical03402.57
InMode00403.00

Outset Medical presently has a consensus target price of $56.50, suggesting a potential upside of 4.82%. InMode has a consensus target price of $71.50, suggesting a potential downside of 18.11%. Given Outset Medical's higher possible upside, research analysts plainly believe Outset Medical is more favorable than InMode.

Valuation & Earnings

This table compares Outset Medical and InMode's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Outset MedicalN/AN/AN/AN/AN/A
InMode$156.36 million17.85$61.15 million$1.6054.57

InMode has higher revenue and earnings than Outset Medical.

Institutional & Insider Ownership

84.6% of Outset Medical shares are owned by institutional investors. Comparatively, 35.7% of InMode shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

InMode beats Outset Medical on 5 of the 7 factors compared between the two stocks.

BioLife Solutions (NASDAQ:BLFS) and InMode (NASDAQ:INMD) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Institutional and Insider Ownership

67.7% of BioLife Solutions shares are owned by institutional investors. Comparatively, 35.7% of InMode shares are owned by institutional investors. 22.3% of BioLife Solutions shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares BioLife Solutions and InMode's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioLife Solutions12.67%0.53%0.43%
InMode32.57%28.56%24.14%

Analyst Ratings

This is a summary of recent ratings and price targets for BioLife Solutions and InMode, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioLife Solutions01902.90
InMode00403.00

BioLife Solutions presently has a consensus target price of $46.6667, suggesting a potential upside of 36.57%. InMode has a consensus target price of $71.50, suggesting a potential downside of 18.11%. Given BioLife Solutions' higher possible upside, analysts clearly believe BioLife Solutions is more favorable than InMode.

Valuation and Earnings

This table compares BioLife Solutions and InMode's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioLife Solutions$27.37 million41.70$-1,660,000.00$0.08427.13
InMode$156.36 million17.85$61.15 million$1.6054.57

InMode has higher revenue and earnings than BioLife Solutions. InMode is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

BioLife Solutions has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500. Comparatively, InMode has a beta of 1.95, indicating that its stock price is 95% more volatile than the S&P 500.

Summary

InMode beats BioLife Solutions on 9 of the 14 factors compared between the two stocks.

Natus Medical (NASDAQ:NTUS) and InMode (NASDAQ:INMD) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Institutional and Insider Ownership

89.7% of Natus Medical shares are owned by institutional investors. Comparatively, 35.7% of InMode shares are owned by institutional investors. 1.5% of Natus Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Natus Medical and InMode's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Natus Medical-4.33%3.87%2.50%
InMode32.57%28.56%24.14%

Analyst Ratings

This is a summary of recent ratings and price targets for Natus Medical and InMode, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Natus Medical01002.00
InMode00403.00

InMode has a consensus target price of $71.50, suggesting a potential downside of 18.11%. Given InMode's stronger consensus rating and higher possible upside, analysts clearly believe InMode is more favorable than Natus Medical.

Valuation and Earnings

This table compares Natus Medical and InMode's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Natus Medical$495.52 million1.93$-15,670,000.00$1.2422.76
InMode$156.36 million17.85$61.15 million$1.6054.57

InMode has lower revenue, but higher earnings than Natus Medical. Natus Medical is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Natus Medical has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500. Comparatively, InMode has a beta of 1.95, indicating that its stock price is 95% more volatile than the S&P 500.

Summary

InMode beats Natus Medical on 11 of the 14 factors compared between the two stocks.

AxoGen (NASDAQ:AXGN) and InMode (NASDAQ:INMD) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Analyst Ratings

This is a summary of recent ratings and price targets for AxoGen and InMode, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AxoGen02302.60
InMode00403.00

AxoGen presently has a consensus target price of $23.75, suggesting a potential upside of 25.99%. InMode has a consensus target price of $71.50, suggesting a potential downside of 18.11%. Given AxoGen's higher possible upside, analysts clearly believe AxoGen is more favorable than InMode.

Institutional and Insider Ownership

78.4% of AxoGen shares are owned by institutional investors. Comparatively, 35.7% of InMode shares are owned by institutional investors. 6.9% of AxoGen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

AxoGen has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Comparatively, InMode has a beta of 1.95, indicating that its stock price is 95% more volatile than the S&P 500.

Valuation and Earnings

This table compares AxoGen and InMode's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AxoGen$106.71 million7.20$-29,140,000.00($0.68)-27.72
InMode$156.36 million17.85$61.15 million$1.6054.57

InMode has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares AxoGen and InMode's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AxoGen-22.98%-19.83%-14.88%
InMode32.57%28.56%24.14%

Summary

InMode beats AxoGen on 11 of the 14 factors compared between the two stocks.


InMode Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
LivaNova logo
LIVN
LivaNova
1.5$81.34-1.8%$3.96 billion$1.08 billion-18.92Analyst Report
Analyst Revision
CONMED logo
CNMD
CONMED
1.6$130.21-0.8%$3.79 billion$955.10 million-3,255.25Analyst Revision
Outset Medical logo
OM
Outset Medical
1.0$53.90-0.2%$2.31 billionN/A0.00Analyst Downgrade
Insider Selling
BioLife Solutions logo
BLFS
BioLife Solutions
2.1$34.17-1.4%$1.14 billion$27.37 million-46.81Insider Selling
Increase in Short Interest
Gap Up
NTUS
Natus Medical
1.1$28.22-0.9%$955.92 million$495.52 million-51.31
AxoGen logo
AXGN
AxoGen
1.7$18.85-3.4%$768.55 million$106.71 million-29.92Gap Down
TransMedics Group logo
TMDX
TransMedics Group
1.6$27.03-2.1%$739.81 million$23.60 million-19.31Increase in Short Interest
ViewRay logo
VRAY
ViewRay
1.3$4.38-1.4%$704.31 million$87.78 million-4.92
Cutera logo
CUTR
Cutera
1.3$30.17-1.8%$536.51 million$181.71 million-16.67News Coverage
Zynex logo
ZYXI
Zynex
1.8$15.36-0.2%$535.37 million$45.47 million46.55News Coverage
Edap Tms logo
EDAP
Edap Tms
1.3$9.08-0.3%$264.61 million$50.23 million-151.33Increase in Short Interest
Second Sight Medical Products logo
EYES
Second Sight Medical Products
0.8$7.36-11.4%$171.12 million$3.38 million-3.85Decrease in Short Interest
Gap Down
BioSig Technologies logo
BSGM
BioSig Technologies
0.5$3.88-4.4%$123.35 millionN/A0.00Gap Down
FONR
FONAR
1.1$18.32-2.9%$120.07 million$85.69 million17.28News Coverage
IRIDEX logo
IRIX
IRIDEX
0.9$7.71-3.0%$119.67 million$43.45 million-14.02Gap Up
Soleno Therapeutics logo
SLNO
Soleno Therapeutics
1.9$1.15-2.6%$91.68 millionN/A-1.51Increase in Short Interest
Gap Down
ENDRA Life Sciences logo
NDRA
ENDRA Life Sciences
0.6$2.18-1.8%$90.69 million$10,000.00-1.18Analyst Upgrade
Increase in Short Interest
electroCore logo
ECOR
electroCore
1.4$1.79-1.7%$86.77 million$2.39 million-2.27Decrease in Short Interest
Gap Up
Helius Medical Technologies logo
HSDT
Helius Medical Technologies
1.3$16.90-1.3%$39.06 million$1.50 million-0.97Analyst Upgrade
Increase in Short Interest
News Coverage
CHF Solutions logo
CHFS
CHF Solutions
1.7$5.37-0.4%$32.42 million$5.51 million-0.11Analyst Downgrade
Increase in Short Interest
News Coverage
Viveve Medical logo
VIVE
Viveve Medical
0.9$2.63-5.7%$27.20 million$6.57 million-0.01News Coverage
Gap Down
STRR
Star Equity
0.1$2.80-5.4%$13.78 million$114.18 million-0.89Gap Down
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.